SAR425899 was developed for the treatment of patients with T2D and obesity 11,12,13,14 aiming to lower glucose at least similar to marketed GLP-1 agonists, but with superior weight loss over GLP-1 receptor mono-agonists
Start your intake What Clinical Evidence Shows About GLP-1 and Long-Term Use Major clinical trials, including SUSTAIN-6 for semaglutide and SURMOUNT studies for tirzepatide, followed patients for 68 weeks to over two years
BOC Sciences (2024)
GLP-1s are shaping how people eat, drink, shop, and exercise, and brands need to be paying close attention to these trends. Also referencing the KFF survey, Shil Kothari, president at Gateway Health Alliances Inc., Fairfield, Calif., explains that the awareness of GLP-1s mean that beverage manufacturers must play a proactive role in offering solutions that support those using these medications
But how exactly can a medication like semaglutide cause fever